David Begley PhD is Senior Lecturer in Physiology at Kings College London. He heads a laboratory within in the Institute of Pharmaceutical Sciences at Kings College investigating the blood-brain barrier and drug delivery to the CNS with a special emphasis on lysosomal storage diseases. Dr Begley was the Friedrich Mertz Stiftungsgast professor, Johann Wolfgang Goethe-Universität, Frankfurt, for the academic year 1997-1998 and was visiting Academic in Residence, GlaxoSmithKline 2005-2007. He was Organiser and Chairman of the Gordon Conference on “Barriers of the CNS” held in New Hampshire in 2002. He is a constituent part of the Pharmaceutical Sciences Research Division, one of the major world recognized opinion leader in the field of Blood Brain Barrier function. He has contributed to the understanding of the function of BBB, of possible effects of storage and secondary effects of storage on the BBB. The blood-brain barrier (BBB) group at Kings College London (KCL) is a constituent part of the Pharmaceutical Sciences Research Divisionand it is one of the leading groups in this area and is recognized worldwide. The laboratory has a wide experience, using both in vivo and in vitro techniques, of BBB transport studies. Current work ranges from a purely scientific study of the function of the normal BBB, to pathology of the BBB in disease. Extensive expertise is available in understanding the problems of drug delivery to the brain to treat CNS disease, Dr Begley is frequently consulted by pharmaceutical companies and work in close collaboration with a number of large companies. In recent years he have been studying the involvement of the BBB in mouse models of mucopolysaccharidosis (MPS IIIA and MPS IIIB) and the problems of delivering therapy to the brain.